These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 36571695)

  • 21. Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.
    R Teixeira M; Oliveira J; Borralho P; O Fernandes MG; Almodovar T; Fernandes I; Macedo D; Ferreira A; Barroso A; Teixeira E; Machado JC
    Acta Med Port; 2022 Sep; 35(9):677-690. PubMed ID: 35816050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updates in the molecular pathology of non-small cell lung cancer.
    Paver E; O'Toole S; Cheng XM; Mahar A; Cooper WA
    Semin Diagn Pathol; 2021 Sep; 38(5):54-61. PubMed ID: 33985831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
    Brisudova A; Skarda J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
    Provencio M; Cobo M; Rodriguez-Abreu D; Calvo V; Carcereny E; Cantero A; Bernabé R; Benitez G; Castro RL; Massutí B; Del Barco E; García Campelo R; Guirado M; Camps C; Ortega AL; González Larriba JL; Sánchez A; Casal J; Sala MA; Juan-Vidal O; Bosch-Barrera J; Oramas J; Dómine M; Trigo JM; Blanco R; Calzas J; Morilla I; Padilla A; Pimentao J; Sousa PA; Torrente M
    BMC Cancer; 2022 Jul; 22(1):732. PubMed ID: 35790916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
    Ekin Z; Nart D; Savaş P; Veral A
    Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Felip E; Concha Á; de Castro J; Gómez-Román J; Garrido P; Ramírez J; Isla D; Sanz J; Paz-Ares L; López-Ríos F
    Clin Transl Oncol; 2015 Feb; 17(2):103-12. PubMed ID: 25351175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision medicine in non-small cell lung cancer: Current applications and future directions.
    Yang SR; Schultheis AM; Yu H; Mandelker D; Ladanyi M; Büttner R
    Semin Cancer Biol; 2022 Sep; 84():184-198. PubMed ID: 32730814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and predictive biomarkers in non-small cell lung carcinoma.
    Odintsov I; Sholl LM
    Pathology; 2024 Mar; 56(2):192-204. PubMed ID: 38199926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
    Canberk S; Engels M
    Virchows Arch; 2021 Jan; 478(1):45-57. PubMed ID: 33389149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia.
    Mitsudomi T; Tan D; Yang JC; Ahn MJ; Batra U; Cho BC; Cornelio G; Lim T; Mok T; Prabhash K; Reungwetwattana T; Ren SX; Singh N; Toyooka S; Wu YL; Yang PC; Yatabe Y
    J Thorac Oncol; 2023 Apr; 18(4):436-446. PubMed ID: 36379356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
    Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
    Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?
    Rossi G; Ragazzi M; Tamagnini I; Mengoli MC; Vincenzi G; Barbieri F; Piccioli S; Bisagni A; Vavala T; Righi L; Novello S; Gelsomino F; Tiseo M
    Curr Drug Targets; 2017; 18(1):13-26. PubMed ID: 25901525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
    Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
    Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
    Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
    Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
    Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
    Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.
    Mitiushkina NV; Romanko AA; Preobrazhenskaya EV; Tiurin VI; Ermachenkova TI; Martianov AS; Mulkidjan RS; Sokolova TN; Kholmatov MM; Bizin IV; Ivantsov AO; Yatsuk OS; Zaitseva OA; Iyevleva AG; Kuligina ES; Imyanitov EN
    Cancer Med; 2022 Sep; 11(17):3226-3237. PubMed ID: 35322575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
    ;
    Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(27):2037-2074. PubMed ID: 37455124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.
    Chen JA; Riess JW
    Curr Treat Options Oncol; 2020 Jun; 21(7):60. PubMed ID: 32588244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.